Regeneus Ltd (ASX:RGS) Quarterly Report

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

The financial highlights for the quarterly reporting period include:

- Cash as at 31 December 2018 of $1.1 million (30 September $2.7 million)

- Net operating cash outflow for the quarter of $1.6 million, consistent with prior quarters

The Company's cash position was $1.1 million as at 31 December. The sources of funding for the Company over the next 18 months include: loan arrangements such as extension to current loan facilities; milestone payments and anticipated clinical licensing opportunities for Progenza; shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013; ongoing R&D Tax Incentives including forward funding arrangements where necessary; capital raisings and existing options exercised. These sources of cash are expected to provide sufficient funding to support the Company's R&D, clinical trials and operating activities for FY'19 and into FY'20.

To view the release, please visit:
http://abnnewswire.net/lnk/13S8Q96D


About Regeneus Ltd

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

      

Related Companies

Regeneus Ltd